KLK3 and prostate carcinoma: We found that only three patients in the Prostaflog® group showed a significant reduction in total PSA value while having positive mpMRI findings (6%), compared with nine in the Serenoa Repens group (19.5%) (p < 0.001), thereby showing that the risk of lowering PSA caused by prostate cancer by means of a hormonal pathway is very low.